Search results | Menarini

Reports

Partnering Agreements with Menarini

This report provides all the information you require to better understand Menarini and its partnering interests and activities over the past seven years.

Insights

Menarini

Menarini is a top pharmaceutical company based in Florence, Italy

Menarini – Dominating the Italian pharmaceutical scene

Menarini or Menarini Group as it is widely known is a large global pharmaceutical company developing treatments for a number of diseases including cardiovascular, gastrointestinal and pain/inflammation.

Menarini: M&A activity 2005-2013

Menarini has announced 2 M&A deals since 2005, with the deals being the acquisition of Invida Holdings and Silicon Biosystems.

Menarini: Partnering activity 2005-2013

Menarini announced 20 partnering / licensing deals since 2005. Analysis of the partnering deals shows a strong emphasis on partnerships in oncology and central nervous system diseases.

Menarini: Company Profile

Menarini, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Deal later, deal selectively: big pharma partnering trends 2005-2013

Smaller, more targeted deals may be the way of the future as big pharma partnering seeks to outsource early stage R&D and risk

Top twenty partnering/licensing deals in 2012 had a combined value of over $20 billion

Analysis of data from the leading life science deals and alliances intelligence database Current Agreements and recently published Partnering Yearbook 2013 report series, shows that the top twenty partnering deals in the life sciences have a combined value of $20.6 billion

Current Agreements Deal Analysis Update: November 2012

This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in October 2012

Pharma news: Spanish Drugmakers Fleeing Crisis Follow Almirall’s Path

Pharma news reports that, As Spain’s economy was booming more than a decade ago, drugmaker Almirall SA (ALM) decided it was time to boost international sales, treading a path that other companies are now following to offset health cuts in the debt-ravaged country

Events

Sorry, your search returned no results.


Deals

Pharma partners, Menarini and Oxford Biotherapeutics, invest $1.1 billion in AML drug candidate

In October 2012, Pharma partners, Menarini and Oxford BioTherapeutics announce a strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer.

Menarini pharma deals Vivus for SPEDRA licensing

VIVUS enters pharma deals with big pharma Menarini for license of SPEDRA in over 40 European countries plus Australia and New Zealand and supply agreement.

Big pharma Menarini unites with Oxford BioTherapeutics in pharma partners pact

Menarini, a big pharma company and Oxford BioTherapeutics announced a major innovative and strategic pharma partners alliance to develop a portfolio of antibody-based drugs in the field of cancer

Pharma licensing deal: Menarini acquires marketing rights for Priligy from Furiex

Menarini Group, a top big pharma company announced that they have entered into a pharma licensing agreement with Furiex Pharmaceuticals by which Furiex will license to Menarini rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East

Menarini succeeds in bid for Invida

Menarini has acquired Invida Holdings